Section Arrow
Quote
APVO.NASDAQ
- Aptevo Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/07 00:48 EDT
Last
 3.04
0 (0.00%)
Day High 
3.05 
Prev. Close
3.04 
1-M High
13.1099 
Volume 
130.20K 
Bid
2.99
Ask
3.05
Day Low
2.9301 
Open
3 
1-M Low
2.81 
Market Cap 
8.71M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 3.46 
20-SMA 3.95 
50-SMA 6.46 
52-W High 485.366 
52-W Low 2.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-325.05/-289.80
Enterprise Value
13.34M
Balance Sheet
Book Value Per Share
-0.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.0.9292+0.1592+20.68%0.84PE
LIXTLixte Biotechnology Holdings2.83+0.81+40.10%-- 
NCNANuCana plc0.0536-0.0029-5.13%-- 
CMNDClearmind Medicine1.1+0.197+21.82%0.16PE
VORVor Biopharma1.91+0.46+31.72%-- 
Quotes are at least 15-min delayed：2025/07/07 00:48 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.